§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US5155108A Expired / Lapsed US ⏱️ 0.0 years remaining

Imidazopyridazines and use as antiasthmatic agents

Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1991-01-30
•
Granted: 1992-10-13
•
Expires: 2011-01-30
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The imidazo[1,2-b]pyridazine compounds of the formula: ##STR1## wherein R 1 is a hydrogen or halogen atom, or a lower alkyl group optionally having substituent(s), R 2 an R 3 are, independently, a hydrogen atom, a lower alkyl group optionally having substituent(s), a cycloalkyl group or a phenyl group optionally having substituent(s) or R 2 and R 3 together with the adjacent nitrogen atom to which they bond may form a heterocyclic ring optionally having substituent(s), X is an oxygen atom or S(O)n (n=0 to 2), Alk is a straight or branched chain alkylene group containing 1-10 carbon atoms and optionally having substituent(s), or their pharmaceutically acceptable salts which possess antiallergic, anti-inflammatory and anti-PAF activities, and their production and use.

Inventors

  • 👤 Akio Miyake
  • 👤 Masaaki Kuwahara
  • 👤 Hisashi Kuriki

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 09:34
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/04

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 5 words
6-[(2,2-Diethyl-3-sulfamoylpropyl)oxy]imidazo[1,2-b] pyridazine or its salt.
Claim 2
Dependent Claim 5 words
6-[(2,2-Diethyl-3-sulfamoylpropyl)oxy]imidazo[1,2-b] pyridazine or its salt.
Claim 3
Dependent Claim 11 words
A compound of claim 1 which is a hydrochloric acid salt.
Claim 4
Dependent Claim 19 words
A pharmaceutical composition comprising 6-[(2,2-diethyl-3-sulfamoylpropyl)oxy]imidazo[1,2-b] pyridazine or its pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier or diluent.
Claim 5
Dependent Claim 19 words
A pharmaceutical composition comprising 6-[(2,2-diethyl-3-sulfamoylpropyl)oxy]imidazo[1,2-b] pyridazine or its pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier or diluent.
Claim 6
Dependent Claim 13 words
A pharmaceutical composition of claim 3 which is used as an antiasthmatic agent.
Claim 7
Dependent Claim 32 words
A method of treating asthma which comprises administering an effective anti-asthmatic amount of a compound of claim 1 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or diluent, to mammals.
Claim 8
Dependent Claim 16 words
A pharmaceutical composition comprising an effective anti-asthmatic amount of 6-[(2,2-diethyl-3-sulfamoylpropyl)oxy]imidazo[1,2-b]pyridazine or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim 16 words
A pharmaceutical composition comprising an effective anti-asthmatic amount of 6-[(2,2-diethyl-3-sulfamoylpropyl)oxy]imidazo[1,2-b]pyridazine or a pharmaceutically acceptable salt thereof.

References Cited (Backward Citations)

GB1135893A Cited
DE2820938A1 Cited
US4307094A Cited
EP0164252A2 Cited
EP0185346A2 Cited
EP0203271A2 Cited
EP0225522A1 Cited
EP0238070A2 Cited
EP0305093A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-10-13 1996-04-13 1996-10-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-10-13 2000-04-13 2000-10-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-10-13 2004-04-13 2004-10-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag